MedTrace Logo

The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation

NCT02581202 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 216

Last updated 2019-06-06

Study results available
· View outcomes & findings →

Summary

This study seeks to assess the virologic effectiveness of dual therapy (lopinavir/ ritonavir (LPV/r) + lamivudine (3TC)) in treatment-experienced human immunodeficiency virus 1 (HIV-1) infected participants with an undetectable plasma HIV-1 (ribonucleic acid) RNA level (for at least 6 months) at the 48 week time point of treatment in the routine clinical settings of the Russian Federation.

Conditions

  • HIV-1 Infection

Interventions

DRUG

lopinavir/ritonavir

tablet

DRUG

lamivudine

tablet

Sponsors & Collaborators

Principal Investigators

  • Andrey Strugovschikov, MD · AbbVie

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-21
Primary Completion
2017-05-27
Completion
2017-05-27

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02581202 on ClinicalTrials.gov